Equity Profile

CYTK

Cytokinetics, Incorporated

Health CareBiotechnology$10.4B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Cytokinetics Misses on EPS, Stock Up 16.71%

Metric	Actual	Expected	Surprise
EPS	$-1.67	$-1.65	-0.18%
Revenue	—	$9M	—

management commentary, guidance changes, and full analysis available with Pro.

Cytokinetics Misses on EPS, Stock Up 16.71%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.67	$-1.65	-0.18%
Revenue	—	$9M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Cytokinetics reported a wider loss than expected for the first quarter of 2026, which typically might concern investors. However, the stock surged by 16.71%, indicating that investors may be optimistic about future developments or other underlying factors not captured in the earnings report. The lack of revenue data could also mean that investors are focusing on other aspects of the company's potential.

Company Snapshot

Cytokinetics, Incorporated is a biotechnology company focused on developing treatments for serious diseases related to muscle function. With a market cap of $8 billion, it plays a significant role in the health care sector, particularly in addressing conditions that affect muscle strength and mobility.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.65

Revenue

Revenue figures help gauge the company's ability to generate sales and are crucial for assessing growth potential.

$9M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

In Q4-2025, Cytokinetics reported an EPS of $-1.50, slightly missing expectations, which led to a modest stock increase of 2.70% the following day. The company continues to navigate challenges in revenue generation.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Cytokinetics to report a loss this quarter, with a consensus EPS of $-1.65 and revenue of $9 million. Investors are particularly focused on how the company manages its costs and revenue growth.

Bull Case

If Cytokinetics can exceed revenue expectations and show signs of improved cost management, it could signal a turnaround in its financial performance, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports higher losses than anticipated, it may lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$-1.65

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$9M

Revenue figures help gauge the company's ability to generate sales and are crucial for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Cytokinetics achieve revenue of at least $9 million this quarter?

Meeting or exceeding this revenue target is crucial for demonstrating growth and attracting investor confidence.

What specific strategies is management implementing to reduce losses this quarter?

Investors will be keen to understand how the company plans to manage costs and improve its financial outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Cytokinetics' potential for revenue growth, especially given recent advancements in their product pipeline.

Supporting Evidence

The options market is pricing in a 44.97% move, indicating expectations for significant volatility that may not align with historical performance.

Cytokinetics has a history of surprising analysts, as seen in previous quarters where they exceeded EPS expectations despite losses.

Key Risk

If revenue comes in significantly above the $9 million consensus, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to stabilize its financial situation after recent challenges.

Bull Confirmed If

Achieving revenue above $9 million would confirm the bull case and suggest a positive trend in sales.

Bear Confirmed If

Reporting revenue below $4 million would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±44.97%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move in the stock, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±43.0% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.7%

30d HV

39.8%

Calls (519K)P/C Ratio: 0.47Puts (242K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests the stock could rise by an average of 2.39%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss expectations, history suggests a potential decline of around 2.39%, which could heighten concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Specific commentary on cost management strategies and their expected impact.
3Insights into customer demand and market conditions affecting sales.
4Management's outlook for the next quarter and any guidance provided.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.65

Revenue

Revenue figures help gauge the company's ability to generate sales and are crucial for assessing growth potential.

$9M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Cytokinetics can exceed revenue expectations and show signs of improved cost management, it could signal a turnaround in its financial performance, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports higher losses than anticipated, it may lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$-1.65

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$9M

Revenue figures help gauge the company's ability to generate sales and are crucial for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Cytokinetics achieve revenue of at least $9 million this quarter?

Meeting or exceeding this revenue target is crucial for demonstrating growth and attracting investor confidence.

What specific strategies is management implementing to reduce losses this quarter?

Investors will be keen to understand how the company plans to manage costs and improve its financial outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Cytokinetics' potential for revenue growth, especially given recent advancements in their product pipeline.

Supporting Evidence

The options market is pricing in a 44.97% move, indicating expectations for significant volatility that may not align with historical performance.

Cytokinetics has a history of surprising analysts, as seen in previous quarters where they exceeded EPS expectations despite losses.

Key Risk

If revenue comes in significantly above the $9 million consensus, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to stabilize its financial situation after recent challenges.

Bull Confirmed If

Achieving revenue above $9 million would confirm the bull case and suggest a positive trend in sales.

Bear Confirmed If

Reporting revenue below $4 million would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±44.97%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move in the stock, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±43.0% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.7%

30d HV

39.8%

Calls (519K)P/C Ratio: 0.47Puts (242K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests the stock could rise by an average of 2.39%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss expectations, history suggests a potential decline of around 2.39%, which could heighten concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Specific commentary on cost management strategies and their expected impact.
3Insights into customer demand and market conditions affecting sales.
4Management's outlook for the next quarter and any guidance provided.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.